Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group, and Corning Incorporated (NYSE: GLW) today announced a collaboration to bring Corning® Epic® label-free detection technology to India.
“This collaboration highlights the growing adoption of label-free technology and the biological insights it enables in drug discovery research”
The collaboration between Advinus and Corning enables Advinus to leverage the Corning Epic technology to enhance its own drug discovery capabilities and to provide assay development and screening services to companies both in India and abroad. "This collaboration is in line with Corning's strategy of bringing innovative technology to India through collaborations with leading Indian companies," said Rustom Desai, President, Corning India.
Corning Epic technology combines biochemical detection and cellular analysis on a single label-free platform to enable a better understanding of biological activity for a wide range of research applications. Corning's technology helps accurately identify targets, pathways, and interactions, providing more biologically relevant data to the drug discovery process.
Commenting on the collaboration, Dr. Kasim Mookhtiar, the CSO of Advinus, said, "This collaboration on Corning's Epic technology emphasizes Advinus' commitment to set up unique Pharma R & D services in India and to explore new and cutting-edge technologies to enhance our drug discovery capabilities. We are excited about the opportunities this will open for our customers and for our relationship with Corning in the area of enhanced drug discovery."
"This collaboration highlights the growing adoption of label-free technology and the biological insights it enables in drug discovery research," said Ron Verkleeren, director, Advanced Life Sciences. "We believe this is an important step forward in making our Epic technology more accessible to life science researchers worldwide."
Squid-inspired technology could replace needles for medications and vaccines